Carina Hillenbach

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

Tudor–Eliade Ciuleanu, Lilia Stelmakh, Saulius Cicėnas et al. · The Lancet Oncology · 2012 · 371 citations

Second-line Treatment, Oncology, Cancer Management +6

Thromboembolic and Bleeding Complications Following St. Jude Medical Valve Replacement

Detlef Hering, Cornelia Piper, R Bergemann et al. · CHEST Journal · 2005 · 150 citations

Thrombosis, Venous Thrombosis, Vascular Surgery +7

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study

Christian Jackisch, S.-B. Kim, Semiglazov Vf et al. · Annals of Oncology · 2014 · 110 citations · Full text

Breast Oncology, Oncology, Pharmacology +5

Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer

Angelica Quartino, Carina Hillenbach, Jing Li et al. · Cancer Chemotherapy and Pharmacology · 2015 · 72 citations · Full text

Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma

David Propper, John Bridgewater, Limas Kupčinskas et al. · Annals of Oncology · 2014 · 44 citations